Pure Global AI
NCT06297603Recruiting

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes, Moderate or Severe Renal Impairment With Inadequate Glycemic Control on Basal Insulin With or Without Metformin and/or SGLT2 Inhibitor
Eli Lilly and CompanyPhase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Type 2 Diabetes
Drug/Device/Intervention
Retatrutide
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Eli Lilly and Company
Location
Sun City West,La Mesa,Torrance,Fleming Island,Idaho Falls,Topeka,Billings,Reno,Albany,Buffalo,Long Island City,Chapel Hill,Hickory,Cleveland,Tulsa,Pittsburgh,Bartlett,Dallas,Houston,Houston,Mesquite,S, Argentina,Puerto Rico,United Kingdom,United States of America
Timeline & enrollment
Phase
Phase 3
Start date
Mar 15, 2024
End date
Oct 09, 2026
Enrollment
320 participants
Primary outcome

Change from Baseline in Hemoglobin A1c (HbA1c) (%)

Summary

The purpose of this study is to investigate the efficacy and safety of retatrutide compared
 with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate
 glycemic control on basal insulin alone or a combination of basal insulin with or without
 metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about
 14 months and may include up to 22 visits.

ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06297603
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06297603 through Pure Global AI's free database. This Phase 3 trial is sponsored by Eli Lilly and Company and is currently Recruiting. The study focuses on Type 2 Diabetes. Target enrollment is 320 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.